Answers are grounded in this paper and cite their sources.
Findings reveal that CXCR3 inhibition reduces cell growth in colorectal cancer, suggesting it as a therapeutic target.
Our findings suggest that downregulation of CXCR3 mRNA inhibits colorectal cancer cell growth through inhibition of the AKT‒mTOR pathway. The CXCR3 receptor can be considered a new therapeutic target in colorectal cancer therapy.
No takes yet. Share an insight, caveat, or question.
Azarshin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: